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andnatural health products. Flaxseed accumulatesmany biolog-
ically active compounds and elements including linolenic acid,
linoleic acid, lignans, cyclic peptides, polysaccharides, alka-
loids, cyanogenic glycosides, and cadmium. Most biological
and clinical studies of flaxseed have focused on extracts contain-
ing a-linolenic acid or lignan. Other flaxseed compounds have
received less attention and their activity is not well described.
The benefits of consumption of whole flaxseed fractions such
as oil, mucilage and protein indicate that consideration of the://
ier Ltd. Aentire portfolio of bioactives present is required to associate bio-
logical activity with specific compounds.Introduction
Flaxseed (Linum usitatissimum L.), one of the oldest culti-
vated crops, continues to be widely grown for oil, fiber, and
food (Oomah, 2001). The average worldwide flaxseed pro-
duction between 2007 and 2011 was 1,862,449 tonnes
(FAO, 2011). Flaxseed oil is an excellent source of the
omega-3 fatty acid linolenic acid with typical levels of
55% in the oil (Oomah, 2001) making it ideal for paints,
varnishes, and inks due to its fast polymerization proper-
ties. Increasing demand for edible oil sources with signifi-
cant percentages of omega-3 fatty acids is resulting in
consumption of flaxseed as a functional food. Flaxseed is
also added to animal feed to improve animal reproductive
performance and health (Heimbach, 2009; Turner et al.,
2014).
Mature flaxseed is oblong and flattened, comprising an
embryo with two cotyledons surrounded by a thin endo-
sperm and a smooth, often shiny yellow to dark brown
seed coat (hull) (Fig. 1). The composition of flaxseed is pre-
sented in Table 1 (Hadley, Lacher, & Mitchel-Fetch, 1992;
Smith, 1958). Analysis of brown Canadian flaxseed con-
ducted by the Canadian Grain Commission showed the
average composition of commercial seed was 41% fat,
20% protein, 28% total dietary fiber, 7.7% moisture, and
3.4% ash (DeClercq, 2012). Minor components included:
cyanogenic glycosides, phytic acid, phenolics, trypsin in-
hibitor, linatine, lignans (phytoestrogens), minerals, vita-
mins, cadmium, selenium and cyclolinopeptides (CLs)
(Bhatty, 1995; Matsumoto, Shishido, Morita, Itokawa, &
Takeya, 2002) (Fig. 2).
The reported protein content of flaxseed varies widely
from 10 to 31% (Bajpai, Pandey, & Vasistha, 1985;
Morita et al., 1997; Oomah & Mazza, 1993a; Salunkhe &
Desai, 1986). Approximately 56e70% of the protein is
found in cotyledons and about 30% in the seed coat and
endosperm (Dev, Quensel, & Hansen, 1986; Sosulski &
Bakal, 1969). Flaxseed protein contains higher amounts
of arginine, aspartic acid, and glutamic acid than other
amino acids (Table 2; Bhatty & Cherdkiatgumchai, 1990;
Oomah & Mazza, 1993b). The essential amino acids found
in flaxseed meal are similar in concentration and composi-
tion to those in soybean.ll rights reserved.
Fig. 1. Hand-cut sections of flaxseed (L. usitatissimum L., var. CDC Be-
thune) mounted in distilled water showing anatomical structures. (A)
The side of flaxseed (B) Hand-cut section of flaxseed. Images were ob-
tained (1000 magnification) with a Canon Eos 300D digital camera
mounted on a Zeiss Stemi SV 11 light microscope. The images were
subsequently processed in Photoshop 7.
Fig. 2. Structures of four cyanogenic glycosides (mono-glycosides: li-
namarin, lotaustralin; di-glycosides: linustatin and neolinustatin) and
SDG in flaxseed.
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Cui (2001) reported the content of insoluble and soluble fi-
ber to be 20% and 9%, respectively, whereas Hadley et al.
(1992) reported 30% and 10%, respectively. The differences
likely arise from seed and/or extraction protocols used. Sol-
uble fiber, also known as mucilage, occurs in the seed coatTable 1. Flaxseed composition.
Constituent
(%)
Whole
seed
Cotyledons and embryo Seed coata
With
fat
Without
fat
With
fat
Without
fat
Moisture 7.13 4.31 NRb 7.89 NRb
Nitrogen 4.01 4.64 10.92 3.18 3.52
Oil 38.71 53.20 NRb 1.84 NRb
Fiber
(soluble)
10.22 NRb NRb NRb NRb
Fiber
(insoluble)
30.41 NRb NRb NRb NRb
Ash NRb 3.38 7.95 2.99 3.31
Weight
fraction
NRb 58.60 40.40 41.40 59.96
% of total
oil
96.70 3.30
a Hull.
b Not reported.
Data taken from Hadley et al. (1992), Smith (1958) and source pa-
pers cited therein.and is readily extracted with hot (Cui, Mazza, Oomah, &
Biliaderis, 1994) and less readily with cold water (Paynel
et al., 2013). This soluble fiber includes acidic [composed
of L-rhamnose (25.3%), L-galactose (11.7%), L-fructose
(8.4%), and D-xylose (29.1%)] and neutral polysaccharides
[L-arabinose (20%) and D-xylose/D-galactose (76%)]
(Anderson & Lowe, 1947). Insoluble fiber is composed of
cellulose (7e11%), lignin (2e7%), and acid detergent fiber
(10e14%) (Cui et al., 1994). Flaxseed mucilage arabinoga-
lactans are associated with protein (Ray et al., 2013).
Flaxseed oil content of ranges from 38 to 44% due to ge-
notype and environmental parameters (Oomah & Mazza,
1997; van Uden, Pras, & Woerdenbag, 1994). Microscopic
membrane bound oil bodies, known as oleosomes, are the
main storage form of oil in the endosperm and cotyledons.
Oleosomes may be extracted from other seed components
and they contain CLs (Gui, Shim, & Reaney, 2012). Fatty
acid composition varies among different flaxseed types
and cultivars. The majority of the flaxseed oil (75%) is
found in cotyledons, with much of the remaining oil
(22%) present in the seed coat and endosperm (Dorrell,
1970). The oil is primarily in the form of triacylglycerides
Table 2. Amino acid compositions of flaxseed in comparison to
soybean.
Amino acid Brown flaxseed
(NorLin)1
Yellow
flaxseed
(Omega)1
Soybean2
g/100 g protein
Alanine (Ala) 4.4 4.5 4.1
Arginine (Arg) 9.2 9.4 7.3
Aspartic acid (Asp) 9.3 9.7 11.7
Cystine (Cys) 1.1 1.1 1.1
Glutamic acid (Glu) 19.6 19.7 18.6
Glycine (Gly) 5.8 5.8 4.0
Histidine (His)a 2.2 2.3 2.5
Isoleucine (Ile)a 4.0 4.0 4.7
Leucine (Leu)a 5.8 5.9 7.7
Lysine (Lys)a 4.0 3.9 5.8
Methionine (Met)a 1.5 1.4 1.2
Phenylalanine (Phe)a 4.6 4.7 5.1
Proline (Pro) 3.5 3.5 5.2
Serine (Ser) 4.5 4.6 4.9
Threonine (Thr)a 3.6 3.7 3.6
Tryptophan (Trp)a 1.83 NRb NRb
Tyrosine (Tyr) 2.3 2.3 3.4
Valine (Val)a 4.6 4.7 5.2
a Essential amino acids for humans.
b Not reported.
Data taken from 1Oomah and Mazza (1993b), 2Friedman and Levin
(1989), and 3Bhatty and Cherdkiatgumchai (1990) source papers
cited therein.
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linoleic (17%), oleic (20%), palmitic (6%), and stearic
(4%) acids (Green, 1990). Minor lipids and lipid soluble
compounds include monoacylglycerides, diacylglycerides,
tocopherols, sterols sterol-esters, phospholipids, waxes,
CLs, free fatty acids (FFAs), carotenoids, chlorophyll,
and other compounds. The oxidative instability of renders
flax less desirable for use as cooking oil although flaxseed
oil is used in northern China for cooking (Choo, Birch, &
Dufour, 2007). Australian scientists selected a new genetic
variant; Linola with linoleic acid above 65% and a-lino-
lenic acid (ALA) below 2% that has improved oxidative
stability (Green & Dribnenki, 1994; Haumann, 1990)
compared to conventional flaxseed. Human metabolic path-
ways do not synthesize ALA, an essential polyunsaturated
fatty acid in flaxseed. It is an intermediate in the biosyn-
thesis of hormone-like eicosanoids, which regulate inflam-
mation and immune function in higher animals (Mantzioris,
James, Gibson, & Cleland, 1994, 1995) and may contribute
to effects of dietary flaxseed oil.
Biological effects of flaxseed and flaxseed fractions
There are many flaxseed products that are consumed
including: whole seed, ground whole seed, flaxseed oil,
partially defatted flaxseed meal (usually from expeller
pressing), fully defatted flaxseed meal (from solvent extrac-
tion), flaxseed mucilage extracts, flaxseed hulls, flaxseed
oleosomes and flaxseed alcohol extracts. Each of these
products is associated with specific beneficial healtheffects. Although each fraction contains more than one
bioactive component reports commonly ignore the presence
of a plurality of bioactive compounds in flaxseed fractions
or attribute the effect of a component of the flaxseed on the
observed effect.
Whole flaxseed is widely accepted as a healthy food that
has anticancer activity. Controlled experimental diets have
demonstrated numerous beneficial effects of flaxseed con-
sumption (Clark et al., 1995; Cunnane et al., 1993; Jenkins
et al., 1999). Dietary flaxseed flour (see description below)
reduces epithelial cell proliferation and nuclear aberrations
in female rat mammary glands. This finding indicates that
flaxseed may reduce the growth rate of mammary cancer
(Serraino & Thompson, 1991). Additionally, it has been
found that flaxseed lignan reduces mammary tumor growth
in the later stages of carcinogenesis (Thompson, Seidl,
Rickard, Orcheson, & Fong, 1996). Supplements of 14%
flaxseed oil and 20% flaxseed meal reduce the incidence of
azoxymethane-induced aberrant crypt foci formation in
Fisher 344 male rats (Williams, Verghese, Boateng, et al.,
2007; Williams, Verghese, Walker, et al., 2007). Similarly,
it has been shown that the substitution of cornmeal with flax-
seedmeal (15%) or corn oil with flaxseed oil (15%) in a basal
diet, significantly decreased tumor multiplicity and size in
the small intestine and colon of Fisher 344 male rats. The au-
thors concluded that flaxseed meal and oil are effective
chemo-preventive agents (Bommareddy et al., 2009).
Inclusion of flaxseed products has also been associated
with improvement in blood lipids. Inclusion of 20% flaxseed
in diets of rats decreased total plasma cholesterol, triglycer-
ide (TG), and low-density lipoprotein (LDL) cholesterol by
21, 34, and 23%, respectively. Supplementation with 30%
flaxseed had a more pronounced effect, reducing the same
factors by 33, 67, and 23% (Ratnayake et al., 1992). In hu-
man studies, 15 g/d of flaxseed administered for threemonths
was associated with reduction in serum TG and LDL choles-
terol without any alteration of high-density lipoprotein
(HDL) cholesterol (Bierenbaum, Reichstein, & Watkins,
1993). It has also been reported that consumption of 50 g
flaxseed/day for four weeks lowered the plasma LDL choles-
terol by 8% in young healthy adults (Cunnane et al., 1995).
Indeed, a meta-analysis of studies published from January
1990 to October 2008 revealed a consensus regarding the ef-
fect of flaxseed products on blood lipids. All flaxseed inter-
ventions, included in the analysis, reduced both total
cholesterol [0.10 mmol/L (95% CI: 0.20, 0.00 mmol/L)]
and LDL cholesterol [0.08 mmol/L (95% CI: 0.16,
0.00 mmol/L)]. While flaxseed oil had no significant effect
on either cholesterol or LDL cholesterol. Interventions
with whole flaxseed and lignan enriched supplements (flax-
seed alcoholic extracts) lowered total cholesterol (0.21
and 0.16 mmol/L) and LDL cholesterol (0.28 and
0.16 mmol/L). Female subjects, and individuals with
elevated initial cholesterol concentrations, showed a greater
response. These experimental findings support the hypothe-
sis that flaxseed consumption has a positive effect on
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was demonstrated that consumption of one whole flaxseed
product in the form of a bagel, muffin, bar or bun that con-
taining 30 g of flaxseed by a group of patients displaying pul-
monary artery disease and elevated blood pressure
significantly reduced both systolic and diastolic blood pres-
sure (Rodriguez-Leyva et al., 2013). In this study the authors
reported significant linear correlations between blood pres-
sure lowering effects and markers of flax consumption. Un-
fortunately, none of the correlations were demonstrated to
be causal. Based on the weight of evidence from human clin-
ical trials available prior to 2011 Health Canada’s Food
Directorate concluded that a claim linking consumption of
ground whole flaxseed and blood cholesterol lowering was
warranted (Health Canada, 2014).
While there are many known flaxseed varieties and flax-
seed composition is known to be affected by genotype and
environmental conditions virtually none of the studies of
flaxseed effects on physiology have shown definitively
that the active ingredient is associated with the observed
biological effect. Differential studies that vary just one
metabolic constituent in the diet are more useful but such
studies are rare. In one such study researchers showed
that flaxseed with both high and negligible ALA content
showed that flaxseed with very low ALA content lowered
hypercholesterolemic atherosclerosis in rabbits (Prasad,
Mantha, Muir, & Westcott, 1998). A second approach to
differential analysis has been presented by Marambe,
Shand, and Wanasundara (2011). In their study the diges-
tion of flaxseed protein was compared for whole seed and
for flaxseed meal after removal of mucilage. In vitro digest-
ibility of proteins was slowed by the presence of mucilage.
No biological activity was observed in this study but the
approach could conclusively demonstrate the role of flax-
seed mucilage in flaxseed biological activity. In addition,
researchers commonly associate observed effects with
metabolic differences that may be spurious and uninten-
tionally misleading. Would the low ALA flax studied by
Prasad, Strauss, and Reichart (1999) have evoked the
same profound response of blood pressure on individual
subjects with peripheral artery disease observed by
Rodriguez-Leyva et al. (2013)? Was the flaxseed used in
the Rodriguez-Leyva et al. (2013) study a representative va-
riety or was it anomalous? Is one component of the flaxseed
or multiple components contributing to the biological ef-
fects? While these questions are easily asked where whole
flaxseed is studied it is important to note that similar ques-
tions may be posed when the biological activity of enriched
flaxseed fractions is considered.
Flaxseed oil
Authors of a number of studies have suggested that the
primary benefit of flaxseed oil consumption is due to its
ALA. Flaxseed oil consumption exerts several effects on in-
flammatory mediators and markers depending on dose.
Flaxseed oil given at 14 g/d to human subjects over 4 weeksdecreased the levels of tumor necrosis factor-a (TNF-a),
interleukin-6 (IL-6), and cytokines. A lower dose did not
have this effect (Caughey, Mantzioris, Gibson, Cleland, &
James, 1996; Thies et al., 2001; Wallace, Miles, &
Calder, 2003). Supplementation of the diet with 6% ALA
depressed the levels of IL-6 and IL-10 and increased the
production of TNF-a in mice (Chavali, Zhong, & Forse,
1998). A lower omega-6 to omega-3 fatty acid ratio
decreased atherosclerosis in comparison to a higher ratio
in apolipoprotein E, in LDL receptor double knockout
mice. Feeding Golden Syrian hamsters 20 g/d ALA for
six weeks reduced serum cholesterol by 17e21% (Yang
et al., 2005). However, no changes were found in serum to-
tal cholesterol, LDL cholesterol or HDL cholesterol in
healthy subjects or hyperlipidemic patients (Freese &
Mutanen, 1997; Kestin, Clifton, Belling, & Nestel, 1990;
Sanders & Roshanai, 1983; Singer, Wirth, & Berger,
1990). David (1983) suggested that ALA might lower the
growth rate of breast and colon cancers. It is noteworthy
that almost all the literature extolling the beneficial func-
tions of flaxseed oil fails to confirm that ALA itself, rather
than other bioactive compounds found in flaxseed oil pro-
duced the observed health benefits.
The quality of flaxseed oil is poorly described in most of
the previously mentioned studies. Flaxseed oil contains
bioactive peptides that oxidize over the first few weeks of
storage under nitrogen (Br€uhl et al., 2007). In addition,
flaxseed oil products were not examined during most
studies to determine if markers of oxidation accumulate
in the oil. Oxidation of vegetable oil produces potentially
toxic biologically active compounds (Esterbauer, 1993;
Han & Csallany, 2009). It is interesting that Collins,
Shand, and Drew (2011) observed large differences in flax-
seed oil metabolism of fish fed flaxseed oil that was pro-
tected either by addition of an antioxidant or by a
combination of antioxidant and encapsulation when
compared with an unprotected oil indicating that flaxseed
oil quality may determine ALA metabolism in fish. It is
not known if the effect of oil quality on ALA metabolism
extends to other species but few studies verify the presence
of oxidation products in oil during the research. More
recently, Randall, Reaney, and Drew (2013) observed that
linolenic acid conversion to eicosapentaenoic acid was
enhanced in fish simultaneously fed flaxseed and petrose-
lenic acid (18:1 D6), in the form of coriander oil, a fatty
acid that potentially decreases linoleic acid conversion to
arachidonic acid. Specific fatty acids included in dietary
studies of flaxseed oil may modify ALA metabolism.
Biological activity of flaxseed lignan and lignan
complex
Secoisolariciresinol diglucoside (SDG, MW 686.7), is a
phytochemical and antioxidant that acts as a precursor of
mammalian lignans and a phytoestrogen (Adolphe,
Whiting, Juurlink, Thorpe, & Alcorn, 2010; Prasad, 2004).
Extraction of flaxseed with aqueous alcohol yields a solution
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propanoids and hydroxymethylglutaric acid referred to as
flaxseed lignan complex (FLC). The oil-insoluble complex
is reported to exert multiple physiological effects in animals
and humans. Westcott and Paton (2001) reported a FLC is
composed of 34e38% SDG, 15e21% cinnamic acid gluco-
side and 9.6e11% hydroxymethylglutaric acid. Consump-
tion of the lignans or the FLC is reported to slow the
progression of atherosclerosis in humans and othermammals
(Prasad, 2005, 2009a, 2009b; Zhang et al., 2008). Treatment
of subjects with FLC [40 mg/kg body weight (bw)/d] for
eight weeks suppressed the development of hypercholester-
olemic atherosclerosis by 34% in rabbits (Prasad, 2005). Hy-
percholesterolemic humans were treated with 300 mg or
600mg of FLC for eight weeks. The 300mg dose reduced to-
tal cholesterol and LDL cholesterol by 15 and 17%, respec-
tively, without any change in the ratio of total cholesterol/
HDL cholesterol. A higher dose of 600mg reduced the serum
total cholesterol and LDL cholesterol by 24 and 22%, respec-
tively, with a decrease in the total cholesterol/HDL choles-
terol ratio (Zhang et al., 2008). Prasad (2009b) also found
that FLC was effective in slowing the progression of athero-
sclerosis by 31% in hyperlipidemic rabbits, as well as
reducing oxidative stress.
SDG produced by chemical hydrolysis and isolated from
flax alcohol extracts can present biological activity that is
similar to the complex. SDG can prevent the development
of atherosclerosis and diabetes (Fukumitsu et al., 2008;
Prasad, 1999, 2009b), and additional benefits include modi-
fication of blood lipids and cholesterol levels (Fukumitsu,
Aida, Shimizu, & Toyoda, 2010). As substantial recent re-
views of SDG activity have been presented it is not re-
viewed further here. In some studies alcoholic extracts
that contain SDG have been used without further separa-
tion. These fractions may contain a range of ethanol soluble
compounds including linatine, cyanogenic glycosides, CLs
etc. Interpretation of these studies requires caution.
Biological activity of selected flaxseed components
Based on the complexity of the flaxseed fractions used
for much of the research discussed above it is not possible
to attribute the health benefits of flaxseed consumption to a
sole bioactive component present in flaxseed. The explora-
tion of the biological roles of flaxseed polyunsaturated fatty
acids and lignan has been substantial in contrast to the
modest efforts made on CLs and other components. Others
have recently reviewed much of this research (Carayol,
Grosclaude, & Delpierre, 2010; Landete, 2012; Lane,
Derbyshire, Li, & Brennan, 2014; Katare, Saxena,
Agrawal, Prasad, & Bisen, 2012; Rabetafika, van
Remoortel, Danthine, Paquot, & Blecker, 2011;
Rodriguez-Leyva, Bassett, McCullough, & Pierce, 2010).
Protein and hydrolysates
Flaxseed protein products are rich in arginine, an amino
acid that, when present in the vascular endothelia, canlower blood pressure (Udenigwe et al., 2012). Flaxseed
protein isolates (FPI) fed at 200 mg/kg bw to spontaneously
hypertensive rats (SHR) effectively lowered blood pressure
four hours after administration. Hydrolysis of the FPI fol-
lowed by isolation of a peptide cation rich fraction pro-
duced peptides with highly elevated arginine. This
fraction produced a marked decrease in blood pressure in
the same SHR system in just 2 h. Flaxseed protein, like pro-
tein from other sources, produces bioactive linear peptide
fractions when hydrolyzed by proteases. These fractions
have been tested for a number of modes of action. For
example, flaxseed proteins digested with Flavourzyme in-
hibited angiotensin converting enzyme (Marambe, Shand,
& Wanasundara, 2008). The same protein fraction is also
effective at scavenging hydroxyl radicals. Flaxseed pep-
tides produced by FPI hydrolysis by thermolysin and pro-
nase (Udenigwe & Aluko, 2010) or alcalase (Omoni &
Aluko, 2006) were biologically active in a number of as-
says. A recent review of flaxseed proteins concluded that
the association of flaxseed proteins with mucilage was an
advantage in their applications in food formulations. How-
ever, mucilage increases the viscosity of aqueous solutions
making the separation of protein difficult. It was noted that
preparing protein isolates that were free from mucilage was
technically difficult due to viscosity (Omoni & Aluko,
2006; Udenigwe & Aluko, 2010; Udenigwe, Lin, Hou, &
Aluko, 2009).
Flaxseed protein hydrolysis products may inhibit angio-
tensin I-converting enzyme but only a few studies have
focused on the hydrolysis of flaxseed protein as would
occur under gut conditions (Marambe et al., 2008, 2011)
investigated the in vitro digestion of flaxseed protein and
found that whole ground flaxseed resisted digestion in
both the modeled stomach and intestinal digestion condi-
tions but that treatments that would inactivated flaxseed
protease inhibitors or removed mucilage or both increased
total digestion. The amount of undigested protein in whole
ground seed was just 12%.
Flaxseed mucilage
Effects of flaxseed mucilage on the digestive tract have
been investigated recently in human and animal trials. The
products were supplied in solution or incorporated into
food. As would be expected for consumption of fiber, feel-
ings of satiety and fullness were expressed by subjects
consuming 2.5 g of soluble fiber in contrast to control sub-
jects. A significant decrease in subsequent energy intake
was observed after the flaxseed drink compared to the con-
trol (2937 vs. 3214 kJ). There was no difference in either
appetite ratings or energy intake by subjects that consumed
soluble flaxseed fiber in a drink or as a tablet. Consuming
flaxseed mucilage liquid three times a day was compared
to consuming the same amount in the form of bread
(Kristensen et al., 2012). Fiber consumed by both means
lowered total fasting cholesterol and LDL cholesterol after
seven days. Fecal fat excretion increased with both
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the bread product, increased energy excretion in feces.
The authors concluded that soluble flaxseed fiber might
be used to reduce cholesterol and may be useful in control-
ling energy balance. Similar observations were made for
rats provided soluble flaxseed fiber as part of their diet.
Weight gain was also limited in rats fed soluble fiber and
dietary linseed in contrast to controls (Kristensen,
Knudsen, et al., 2013). The effects of soluble flaxseed fiber
on appetite, blood triglycerides and appetite regulating hor-
mones were observed for seven hours after a test meal
(Kristensen, Savorani, et al., 2013). Higher levels of dietary
fiber served with the meal (3.4 g/MJ from flaxseed) were
associated with decreased blood triglyceride (18%) after
the meal. Additionally, satiety and fullness ratings
increased while insulin decreased with the higher dietary fi-
ber treatment. The concentrations of hormones ghrelin,
cholecystokinin and glucagon-like peptide 1 were not
affected by the treatment.
Polyunsaturated fatty acids, the lignan complex, poly-
saccharides, flaxseed proteins and CLs are major functional
classes of compounds that might impart some or all of the
observed experimental results of flaxseed products. While
compounds associated with health benefits were consumed,
compounds that are also bioactive but potentially toxic
were also present in many of the aforementioned studies.
These compounds include: linatine, cyanogenic glycosides,
cadmium, phytate, selenium, and SDG (Fig. 3). Paradoxi-
cally, these compounds may also have contributed to the
observed health benefits.
Linatine
When fed flaxseed meal as a major portion of the diet
poultry suffer symptoms similar to vitamin B deficiency.
Addition of vitamin B in the form of pyridoxine overcameFig. 3. Classification of plant cyclopeptidesthis deficiency. Linatine, a component of flaxseed meal,
may cause the decreased growth (Klosterman,
Lamoureux, & Parsons, 1967). Most studies have not
demonstrated direct effects of linatine on health but rather
have shown weight gain responses to vitamin B supplemen-
tation. For example it was concluded that linatine did not
affect the performance of swine fed meal from low lino-
lenic acid flaxseed as their growth rate was unaffected by
the inclusion of pyridoxine (Batterham, Andersen, &
Green, 1994). Another route to showing the potential
impact of linatine is to determine the vitamin B status.
Bishara and Walker (1977) fed pigs a diet containing
30% flaxseed meal by dry weight and challenged the test
animals with tryptophan to determine vitamin B status.
An observable change in tryptophan metabolites was re-
ported suggesting that the animals were experiencing mar-
ginal vitamin B6 deficiency (Bishara & Walker, 1977).
While there are no reports of vitamin B deficiency in hu-
mans that have consumed flaxseed this is potentially related
to the relatively lower consumption of flaxseed products as
a portion of diet. The risk of flaxseed causing a deficiency
could be related to the level of consumption and the vitamin
B status of the individual consuming the seed. The elderly,
vegetarians, and vegans have been noted as groups that are
more likely to have a deficiency in vitamin B (Allen, 2009;
Gilsing et al., 2010).Cyanogenic glycosides
Cyanogenic compounds have profound biological ef-
fects. Flaxseed contains linamarin, linustatin and neolinus-
tatin with the potential to release 7.8 mM of cyanogenic
compound/g of flaxseed. A thirty-gram dose of flaxseed
could release 240 mM of cyanide. Researchers have found
no effect of prolonged consumption of flaxseed.modified from Tan and Zhou (2006).
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duce undesirable effects. Consumption of 20% flaxseed
meal by weight of diet counteracted the toxicity of sele-
nium fed in the form of sodium selenite (Olson &
Halverson, 1954). Furthermore, it was discovered that the
protective factor could be extracted from flaxseed meal
by aqueous methanol (MeOH). Chromatography of these
protective extracts revealed that fractions that protected
against selenium toxicity were also rich in the cyanogenic
glycosides linustatin and neolinustatin. HPLC peaks that
contained these compounds and pure linamarin both pro-
vided some protective effect against selenium toxicity
(Palmer, Olson, Halverson, Miller, & Smith, 1980).
The capacity of individuals to detoxify cyanide is related
to the presence of sulfur containing amino acids in the diet.
Most research into the toxicity of cyanogenic compounds to
humans is related to the consumption of cassava as a staple
in the diet. The toxicity of cassava is exacerbated due to the
typical high levels of consumption and the low availability
of dietary protein to those that rely on this staple (World
Health Organization, 2004). The toxicity of flaxseed cyano-
genic glycosides is likely to be rare except in cases where
flaxseed fractions are consumed in relatively large amounts
in low protein diets.
Cadmium
Many plants, including flaxseed, absorb the toxic heavy
metal cadmium from the soil which then accumulates in the
seed. Plant products contribute about two thirds of dietary
cadmium (Satarug, Garrett, Sens, & Sens, 2010). Of this,
whole oilseeds and oilseed meal including products of sun-
flower, peanut and flaxseed represent the richest cadmium
sources. Cadmium toxicity is typically observed as the
loss of kidney function and bone density although many
other symptoms are recognized. These effects are cumula-
tive and may require decades of exposure. For most of the
population exposure to cadmium through food occurs at a
low level. For example, it has been estimated that cadmium
exposure through diet in European countries was 2.3 mg/
kg bw/week (range from 1.9 to 3.0 mg/kg bw/week) though
vegetarians consumed higher levels of cadmium (up to
5.4 mg/kg bw/week) (Alexander et al., 2009).
A Proposed Tolerable Weekly Intake (PTWI) was estab-
lished to be 7 mg/kg bw/week (WHO Food Additives,
1989). The choice of weekly dietary exposure was chosen
over the daily exposure due to the high levels of cadmium
in specific foods and the slow adsorption and excretion
characteristics of cadmium. Cadmium has a very long
half-life in the human system. For a 62 kg human this
amounts to 434 mg/per week (Walpole et al., 2012). Thirty
grams of flaxseed consumption (Leyva et al., 2011) con-
taining 500 mg cadmium/kg (Saastamoinen et al., 2013)
on a daily basis would contribute 105 mg/per week to the
diet or 1.69 mg/kg bw/week. This level of cadmium con-
sumption is below the PTWI and normal exposure levels
for Europeans. However, the Contaminants in the FoodChain (CONTAM) panel (Alexander et al., 2009) advised
that the cadmium TWI recommendation be lowered to pro-
tect more sensitive individuals in the population. Based on
a meta-analysis of kidney function and exposure to cad-
mium it was established that the formerly established
PTWI for cadmium of 7 mg/kg bw/week may place specific
individuals at risk. The panel recommended lowering the
TWI to just 2.5 mg/kg bw. Consumption of 30 g of flax-
seed/day would contribute 70% of the newly proposed
TWI. It is possible that consuming larger amounts of flax-
seed over longer periods of time may place a significant
cadmium burden on susceptible individuals.
Cadmium is toxic to specific cancer cell lines and has
been considered for use in chemotherapy (Waalkes &
Diwan, 1999). However, chronic exposure to cadmium in-
creases the risks of cancer (Satarug et al., 2010).
Cyclolinopeptides
Although CLs have been known for more than half a
century research has largely been restricted to structural
and physical characterization. Most of what is known about
biological activities is anecdotal or based on small animal
studies with modest numbers of specimens or in vitro anal-
ysis. CLs occur as a significant seed component in flaxseed,
but the role of these compounds in planta is largely un-
known. In vitro studies of CL biological activity have
been described in various publications (Gaymes, Cebrat,
Siemion, & Kay, 1997; Gorski et al., 2001; Kessler,
Gehrke, et al., 1986; Kessler, Klein, & Muller, 1986;
Siemion, Cebrat, & Wieczorek, 1999; Wieczorek,
Bengtsson, Trojnar, & Siemion, 1991).
Kessler, Klein, et al. (1986) reported that CLA (1) in-
hibits cholate uptake into hepatocytes. Later, the tripeptide
-Phe-Phe-Pro- observed in isolated form from 1, which is
similar to structures in antamanide and somatostatin, was
proved to suppress the hepatocyte cell transport system.
It is possible that this peptide sequence imparts the
observed cytoprotective effects of 1 on hepatocytes
(Rossi & Bianchini, 1996). Immunomodulatory activity
of 1 was studied using: Jerne’s plaque-forming cell number
determination test for the primary and secondary humoral
immune response, delayed type hypersensitivity reaction,
the skin-allograft rejection, the graft-versus-host reaction
for the cellular immune response in mice, human lympho-
cyte proliferation test in vitro and the post-adjuvant polyar-
thritis test in rats and hemolytic anemia test in New
Zealand black mice (Wieczorek et al., 1991). The results
show 1 affected both the humoral and cellular immune re-
sponses. An increased skin-allograft rejection time and
reduced graft-versus-host reaction index was also observed.
Human lymphocyte proliferation was inhibited in vitro by
1 via phytohemagglutinin (Wieczorek et al., 1991). The
symptoms associated with two immune diseases, post-
adjuvant polyarthritis in rats and hemolytic anemia of
New Zealand black mice, were alleviated. In the research
of Gorski et al. (2001), the immunosuppressive effects of
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immunosuppressant. Both 1 and CsA function by inhibiting
the action of Interleukin-1-a and Interleukin-2. This
finding strongly indicates that 1 shares the same mecha-
nism as CsA in the plaque-forming cells test and the autol-
ogous rosette-forming cells test. This study also compared
the effects of both compounds on human lymphocytes
in vitro. It was found that at very low concentrations, 1
induced the same effects as CsA on T- and B-cell prolifer-
ation, acquisition of activation antigens and immunoglob-
ulin synthesis (Gorski et al., 2001). Overall, these studies
demonstrated that 1 had similar biological effects to CsA.
The toxicity of 1 was evaluated by intravenous and oral
administration in rats and mice (Wieczorek et al., 1991).
Oral administration of 4 g/kg CL 1 in olive oil, 2% gelatin
solution did not harm mice while a concentration of 3 g/kg
in rats was also well tolerated. Intravenous administration
of 1 at 230 mg/kg is non-toxic to mice. The combined
strong immunosuppressive activity and low toxicity at rela-
tively large doses of 1 indicates a potential as an immuno-
suppressive drug.
Other CLs and their analogs were also investigated for
immunosuppressive activities. According to the research
of Morita et al. (1997), CL 2 inhibits concanavalin-A
induced proliferation of human peripheral blood lympho-
cytes at treatment levels comparable to that of CsA. CLs
2 and 9 also manifested a moderate inhibitory effect on
concanavalin-A induced mouse lymphocyte proliferation
(Morita et al., 1997). Many chemical analogs of 1 were
tested for their effects on the immune response (Benedetti
& Pedone, 2005; Picur, Cebrat, Zabrocki, & Siemion,
2006; Siemion et al., 1999). Many of these compounds
including a -Pro-Xxx-Phe- sequence (where Xxx means a
hydrophobic, aliphatic, or aromatic residue) were found
to exert immunosuppressive activity although none of
them were greater than CL 1 (Picur et al., 2006). The
immunosuppressive activity of CLs and analogs make
them potential value-added natural products of flaxseed
and should lead to further investigation of the biological ac-
tivities of CLs.
Flaxseed CLs belong to the peptide class of orbitides
that are plant cyclic peptides produced from ribosomal pre-
cursors (Arnison et al., 2013). These natural products occur
in significant quantities in some plant species. Databases
containing expressed sequence tags and genome sequences
were investigated for information about orbitide biosyn-
thesis. This revealed genes that appeared to encode precur-
sors, which are subsequently cyclized to mature orbitides
(Covello et al., 2012). Moreover, the presence of new orbi-
tides, which were predicted by sequence analysis, has been
confirmed by mass spectrometry (MS) (Okinyo-Owiti,
Young, Burnett, & Reaney, 2014). Sequence analysis also
predicts the presence of many similar precursor genes in
Euphorbiaceae, Caryophyllaceae, Linnaceae, and Rutaceae
(Arnison et al., 2013). These peptides are made of protei-
nogenic amino acids and are produced by ribosomalsynthesis. A more thorough discussion of CLs is provided
below.
Flaxseed CLs are orbitides
Plant cyclopeptides are cyclic compounds found in
higher plants. They typically comprise 2 to 37 amino acids.
The cyclic peptides of flaxseed specifically contain protei-
nogenic amino acids and their oxidized products. Tan and
Zhou (2006) reviewed the chemistry of plant cyclopeptides
and reported structures of 455 cyclopeptides in 24 plant
families. In their review they divided plant cyclopeptides
into two classes, five subclasses, and eight types according
to their bonding structures (Fig. 3). Individual classes were
named according to taxonomic distribution. Cyclopeptide
alkaloids (Type I), Caryophyllaceae-type cyclopeptides
(Type VI), and Cyclotides (Type VIII) are the three largest
groups numbering 185, 168, and 51 members, respectively.
Flaxseed cyclic peptides belong to type VI peptides.
Although Tan and Zhou (2006) classified all cyclopeptides
found in plants calling Type VI cyclopeptides
Caryophyllaceae-type homomonocyclopeptides. This
name was cumbersome and Arnison et al. (2013) suggested
calling homodetic plant cyclic peptides, comprising those
peptides arising from ribosomal synthesis that do not
contain cysteine knots and having 5e12 amino acids, orbi-
tides (Arnison et al., 2013). This distinguishes orbitides
from the cyclotides that contain cysteine knots. CLs are or-
bitides. Both orbitides and cyclotides are homodetic cyclic
peptides as the ring consists solely of amino-acid residues
with N- and C-terminals linked through a peptide bond.
Proposed nomenclature for CLs
CLs were classified as members of the “Caryophyllaceae
Type VI homomonocyclopeptides” that contain eight or
nine amino acid residues with molecular masses of approx-
imately 1 kDa. The first CL (first orbitide CL 1), was iden-
tified after it was isolated from sediments recovered from
crude flaxseed oil (Kaufmann & Tobschirbel, 1959). In
1968, Weygand discovered a similar cyclic nonapeptide,
CL 2. Between 1999 and 2014, 17 CLs (3e6, 8e12, and
14e21) were identified from the seed and root of flax
(Matsumoto, Shishido, Morita, Itokawa, & Takeya, 2001;
Matsumoto et al., 2002; Matsumoto, Shishido, & Takeya,
2001; Morita, Shishido, Matsumoto, Itokawa, & Takeya,
1999; Okinyo-Owiti et al., 2014; Stefanowicz, 2001,
2004). In addition, another cyclic peptide with a non-
proteinaceous amino acid residue (N-methyl-4-
aminoproline) was isolated from Linum album in 1998
(Picur, Lisowski, & Siemion, 1998). Subsequently, cyclic
peptides from flaxseed were named according to the date
of their discovery with each newly discovered peptide be-
ing ascribed the next letter in the alphabet (old name,
Table 3). Type VI nomenclature and flaxseed orbitide
nomenclature are highly irregular with publications
defining novel designations for oxidation products and au-
thors using a single name for two distinct compounds.
Table 3. CLs in L. usitatissimum L.
Code New namea Lit. nameb Amino acid sequence (NaC-)c Chemical formula MW (Da) References
1 [1e9-NaC]-CLA CLA Ile-Leu-Val-Pro-Pro-Phe-Phe-Leu-Ile C57H85N9O9 1040.34 Kaufmann & Tobschirbel, 1959
2 [1e9-NaC]-CLB CLB Met-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile C56H83N9O9S 1058.38 Weygand, 1968; Morita et al., 1997
3 [1e9-NaC],[1-MetO]-CLB CLC MetO-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile C56H83N9O10S 1074.38 Morita et al., 1999
4 [1e9-NaC],[1-MetO2]-CLB CLK MetO2-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile C56H83N9O11S 1090.38 Matsumoto, Shishido, and
Takeya (2001)
5 [1e8-NaC]-CLD CLD’, CLK,d CLOe Met-Leu-Leu-Pro-Phe-Phe-Trp-Ile C57H77N9O8S 1048.34 Stefanowicz, 2001, Stefanowicz,
2004, Okinyo-Owiti et al., 2014
6 [1e8-NaC],[1-MetO]-CLD CLD MetO-Leu-Leu-Pro-Phe-Phe-Trp-Ile C57H77N9O9S 1064.34 Morita et al., 1999
7 [1e8-NaC],[1-MetO2]-CLD 1-Msn-CLD MetO2-Leu-Leu-Pro-Phe-Phe-Trp-Ile C57H77N9O10S 1080.34 Olivia, 2013
8 [1e8-NaC]-CLE CLE’, CLJ,d CLPe Met-Leu-Val-Phe-Pro-Leu-Phe-Ile C51H76N8O8S 961.26 Stefanowicz, 2001, Stefanowicz,
2004, Okinyo-Owiti et al., 2014
9 [1e8-NaC],[1-MetO]-CLE CLE MetO-Leu-Val-Phe-Pro-Leu-Phe-Ile C51H76N8O9S 977.26 Morita et al., 1999
10 [1e8-NaC],[1-MetO2]-CLE CLJ MetO2-Leu-Val-Phe-Pro-Leu-Phe-Ile C51H76N8O10S 993.26 Matsumoto, Shishido, and
Takeya (2001)
11 [1e8-NaC]-CLF CLF, CLL Met-Leu-Met-Pro-Phe-Phe-Trp-Val C55H73N9O8S2 1051.50 Stefanowicz, 2001,
Stefanowicz, 2004
12 [1e8-NaC],[3-MetO]-CLF CLI Met-Leu-MetO-Pro-Phe-Phe-Trp-Val C55H73N9O9S2 1068.35 Matsumoto, Shishido,
Morita, et al., 2001
13 [1e8-NaC],[1-MetO]-CLF (Mso)-LCP-3 MetO-Leu-Met-Pro-Phe-Phe-Trp-Val C55H73N9O9S2 1068.35 Reaney et al., 2013,
14 [1e8-NaC],[1,3-MetO]-CLF CLF MetO-Leu-MetO-Pro-Phe-Phe-Trp-Val C55H73N9O10S2 1084.35 Matsumoto, Shishido,
Morita, et al., 2001
15 [1e8-NaC]-CLG CLG, CLM Met-Leu-Met-Pro-Phe-Phe-Trp-Ile C56H75N9O8S2 1066.38 Stefanowicz, 2001,
Stefanowicz, 2004
16 [1e8-NaC],[3-MetO]-CLG CLN Met-Leu-MetO-Pro-Phe-Phe-Trp-Ile C56H75N9O9S2 1082.38 Stefanowicz, 2004
17 [1e8-NaC],[1-MetO]-CLG CLH MetO-Leu-Met-Pro-Phe-Phe-Trp-Ile C56H75N9O9S2 1082.38 Matsumoto, Shishido,
Morita, et al., 2001
18 [1e8-NaC],[1,3-MetO]-CLG CLG MetO-Leu-MetO-Pro-Phe-Phe-Trp-Ile C56H75N9O10S2 1098.38 Matsumoto, Shishido,
Morita, et al., 2001
19 [1e9-NaC]-CLQ [1e9-NaC]-CLQ Met-Leu-Lys-Pro-Phe-Phe-Phe-Trp-Ile C66H87N11O9S 1210.53 Okinyo-Owiti et al., 2014
20 [1e9-NaC],[1-MetO]-CLQ [1e9-NaC],[1-MetO]-CLQ MetO-Leu-Lys-Pro-Phe-Phe-Phe-Trp-Ile C66H87N11O10S 1226.52 Okinyo-Owiti et al., 2014
21 [1e9-NaC]-CLR [1e9-NaC]-CLS Gly-Ile-Pro-Pro-Phe-Trp-Leu-Thr-Leu C54H76N10O10 1025.24 Okinyo-Owiti et al., 2014
a Post-translational modifications of all ribosomally synthesized and post-translationally modified peptides (RiPPs) are noted according to Arnison et al. (2013). All CLs listed are either a funda-
mental parent structure or oxidized products of a fundamental parent structure. The first recognized compound of each fundamental parent structure is used for all structure names. Fundamental
parent structures are provided for CLA, CLB, CLD, CLE, CLF, CLG, CLQ, and CLR.
b Name used in first literature description (name used in subsequent literature description).
c The methionine residues of amino acid sequences are highlighted in Fig. 4. Abbreviations are MetO for methionine S-oxide and MetO2 for methionine S,S-dioxide.
d Stefanowicz (2004) reused CLJ and CLK for 8 and 5 after these names were used originally for 10 and 4 respectively by Matsumoto, Shishido, and Takeya (2001).
e Okinyo-Owiti et al. (2014) proposed the use of new naming convention of CLO and CLP for Met-containing CLPs to distinguish them from MetO containing forms CLD and CLE, respectively.
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recommendation relating to methionine sulfur oxidation
products is clear. “Indication of the modification of this sul-
fur should not suggest the addition of further sulfur. Hence
calling. methionine S-oxide by the name methionine sulf-
oxide, and methionine S,S-dioxide by the name methionine
sulfone may be confusing and is not recommended.” There-
fore methionine S-oxide and methionine S,S-dioxide are
designated according to notes 1 and 2 (Giles, 1999;
IUBMB/IUPAC, 1993).
Methionine S-oxide ðmethionine oxideÞ MetO or MetO
ð1Þ
Methionine S;S-dioxide ðmethionine dioxideÞ MetO2 orMet
O2
ð2Þ
Designation of the first amino acid in a homodetic cyclic
peptide is problematic and not described by IUPAC. Mass
spectrometry fragmentation has allowed analysts to choose
the preferred first amino acid in each sequence as the N-ter-
minal of the first linear cleavage product in MS/MS analysis.
Now that it is known that mRNA directs orbitide synthesis it
is appropriate that the linear sequence presented for flaxseed
cyclic peptides matches the linear sequence of the DNA and
RNA that gave rise to the cyclic peptide preprotein and pep-
tide. This designation is recommended in a recent review of
all cyclic peptides synthesized from ribosomal precursors
(Arnison et al., 2013). The DNA and amino acid sequences
of the CL precursor protein are provided by Shim, Gui,
Arnison, Wang, and Reaney (2014) and Okinyo-Owiti et
al., 2014. Sequences of DNA bases and amino acids that
are processed to CLs are highlighted (Fig. 4).
The structures proposed nomenclature for CLs (1e21)
are shown in Table 3 and Fig. 5. Linkage [1e#-NaC] oc-
curs between amino acid 1 and amino acid “#” through
the alpha amino group that forms a NeC cyclization of
the core peptide. The en dash (e) is used and placed in
square brackets. Identical amino acids substituents are
numbered and grouped as shown. Modifications of amino
acids use conventions of UniProt and IUPAC in square
brackets. Authors only indicate when there is post-
translational modification, for example, oxidation of the
Met residue to MetO and MetO2 (omitted Met). CL name
(CLX) is recognized by 3 capital letters. There is no provi-
sion for a nomenclature that involves more than 26 CLs.
Fresh aqueous methanolic (70%) extracts of flaxseed
comprise as major CL constituents, 1 and methionine
(Met) containing 2 (Morita et al., 1997; Weygand, 1968),
5, 8, 11, and 15 (Stefanowicz, 2001) (curiously,
Stefanowicz (2004) renamed these same peptides three
years later citing the structures as being “new”. The latter
publication did not cite the earlier report). On the other
hand, aged flaxseed oil contains mainly 1 and methionine
S-oxide (MetO) possessing CLs such as 3, 6, 9, 14, and18 (Reaney et al., 2013). The MetO residues derive from
Met oxidation, with further oxidation of these residues
leading to methionine S,S-dioxide (MetO2) containing
CLs such as 4 and 10 (Fig. 6) (Morita & Takeya, 2010).
CL 1 does not contain Met and is, therefore, not prone to
this form of oxidation. Met oxidation to MetO/MetO2 res-
idue in a given CL could be a good indicator of flaxseed
oil storage duration since these processes occur over a
period of time (Br€uhl et al., 2007; Jadhav, Okinyo-Owiti,
Ahiahonu, & Reaney, 2013). For instance 9 confers a bitter
flavor to linseed oil and is a product of oxidation of 8. The
oxidative transformation of 8 to 9 in freshly prepared oil
begins after 2 days at room temperature and the intensity
of bitterness increases over a period of 20 weeks, corre-
sponding with increasing accumulation of 9 in the oil
(Br€uhl et al., 2007). Met amino acids present in the CLs
present in partially defatted flaxseed products were resistant
to oxidation (Aladedunye, Sosinska, & Przybylski, 2013).
Crystal structure of CLs
The biological activity of orbitides is a product of their 3D
shape and primary amino acid composition. The genome of
flax is published but the primary sequence will provide only
partial information regarding themechanism of protein func-
tion. Detailed 3D structure of each gene product is vital to
understand its full function. The structures of nine different
CLs (1e3, 6, 9, 12, 14, 17, and 18) have been elucidated
by 2D FT-NMR spectroscopy (Matsumoto, Shishido,
Morita, et al., 2001; Matsumoto et al., 2002; Morita et al.,
1999). Structures of 1 with different co-crystallized solvent
molecules have been determined by single-crystal X-ray
diffraction (Di Blasio, Benedetti, Pavone, Pedone, &
Goodman, 1987; Di Blasio et al., 1989; Matsumoto et al.,
2002; Quail, Shen, Reaney, & Sammynaiken, 2009).
Recently, Reaney et al. (2013) have reported the solid state
and solution structures of four CLs using X-ray diffraction
and 2D-NMR. 1, 2, and 4were readily crystallized; two adja-
cent prolines form a cis bond that contributes rigidity to the
molecule (Jadhav et al., 2013). In contrast, 9 and 10, that
contain only one proline residue, do not crystallize readily.
Difficulty in crystallization of compounds containing
MetO may be caused, in part, by the optical activity of the
MetO moiety. It is typically more difficult or impossible to
form crystals of diastereomers.
Conclusions
Flaxseed oil is a rich source of ALA but this oil also
contains cyclic peptides. Most studies of ALA acid are truly
studies of cold pressed flaxseed oil. These studies may erro-
neously attribute biological activity to ALA that is contrib-
uted by cyclic peptides. Additionally the oxidative state of
the oil in many studies is not known. Flaxseed coat mate-
rials are a rich source of lignans and the polysaccharide
mucilage. The latter has profound effects on digestive
health. Studies that attribute biological activity of flaxseed
hull and flaxseed hull extracts to either lignans or
Fig. 4. Structures of CLs. Abbreviations are Ile for Isoleucine, Gly for Glycine, Met for methionine, MetO for methionine S-oxide, and MetO2 for
methionine S,S-dioxide. Predicted products of NCBI genes AFSQ01016651.1 (1, 2, 8, and 19), AFSQ01025165.1 (5, 11, and 15),
AFSQ01011783.1 (21), and AFSQ01011783.1 (21) are highlighted in green, blue, yellow, and yellow, respectively. (For interpretation of the refer-
ences to color in this figure legend, the reader is referred to the web version of this article.)
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tracts of flaxseed meal contain lignans, cyanogenic glyco-
sides and cyclic peptides. These materials may all
contribute biological activity.
Flaxseed cyclic peptide nomenclature has not been
applied with rigor. It is recommended that peptides be
named as described in Table 3 for future publications.
The risk of toxicity from flaxseed consumption due to li-
natine, cyanogenic glycosides and cadmium appears to benegligible for most individuals when flaxseed products are
consumed in moderation. Regular consumption of flaxseed
or flaxseed meal products could place a significant portion
of the “cadmium burden” on individuals. However, current
recommendations for maximumweekly cadmium consump-
tion are not likely to be exceeded with reasonable flaxseed
product consumption levels. The cyanogenic glycoside
levels in flaxseed do not appear to be sufficiently concen-
trated to contribute any biological effect. There is a reported
Fig. 6. Transformation of CL by the chemical oxidation of Met to MetO
and MetO2 modified from Morita and Takeya (2010).
Fig. 5. Proposed nomenclature for CLs.
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This interaction has not been studied in sufficient detail to use
flaxseed as a treatment for selenium poisoning. The level of
the vitamin B antagonist, linatine, in flaxseed has never been
associated with toxicity in humans but the consumption of
large amounts of flaxseed can lead to evidence of limited
vitamin B availability in swine. It is not known if individuals
with compromised vitamin B might become deficient when
consuming flaxseed. The level of linatine is not known for
most current flaxseed varieties and thus it is not possible to
suggest that the dose of this compound is acceptable in un-
tested varieties of flax.Acknowledgments
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